Adult & adolescent ≥12 yr, at least 40 kg Single loading dose of 200 mg on day 1 via IV infusion over 30-120 min on day 1 followed by once daily maintenance doses of 100 mg on day 2. Recommended treatment duration for patients not requiring invasive mechanical ventilation &/or extracorporeal membrane oxygenation (ECMO): 5 days, treatment may be extended for up to 5 days if the patient does not demonstrate clinical improvement.
Hypersensitivity reactions including infusion-related & anaphylactic reactions. Increased risk of elevated transaminase. Discontinue if ALT levels increase to >10 x ULN &/ accompanied by signs/symptoms of liver inflammation. Risk of reduced antiviral activity when coadministered w/ chloroquine phosphate or hydroxychloroquine sulfate. Pregnancy & lactation. Childn <12 yr or w/ wt <40 kg.
J05AB16 - remdesivir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
